Skip to content
value.today

Blend Biosciences, Inc.

🇺🇸 Waltham, Massachusetts, USABiotechnologyFounded 2011
Total raised
$126 M
7 rounds on record
Latest round
$6 M
Sep 2021
First round on record
Aug 2011
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Blend Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2021$6 MNo. 7$2 to $10 million

Blend Biosciences, Inc.: Raise no. 7, Sep 2021

Investors in this round

1 investor had bought by the notice of Sep 27, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Roberts · Executive Officer, Director
  • Aymeric Sallin · Director
  • Dennis Ausiello · Director
  • Guido Magni · Director
  • Michael Metzger · Director
  • Nilesh Kumar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian Roberts, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 27, 2021. Read the notice at the SEC.

equitySEC
Dec 2020$15 MNo. 6$10 to $50 million

Blend Biosciences, Inc.: Raise no. 6, Dec 2020

Investors in this round

8 investors had bought by the notice of Dec 28, 2020: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Roberts · Executive Officer
  • Aymeric Sallin · Director
  • Dennis Ausiello · Director
  • Guido Magni · Director
  • Michael Metzger · Director
  • Nilesh Kumar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian Roberts, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 28, 2020. Read the notice at the SEC.

equitySEC
Dec 2019$14 MNo. 5$10 to $50 million

Blend Biosciences, Inc.: Raise no. 5, Dec 2019

Investors in this round

13 investors had bought by the notice of Dec 26, 2019: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew J. Fromkin · Executive Officer, Director
  • Aymeric J. Sallin · Director
  • Dennis J. Ausiello · Director
  • Guido J. Magni · Director
  • Michael J. Metzger · Director
  • Nilesh J. Kumar · Director
  • Omid J. Farokhzad · Director
  • Robert J. Langer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Fromkin, President. Source: SEC Form D, newest notice filed Dec 26, 2019. Read the notice at the SEC.

equitySEC
Jan 2017$30 MNo. 4$10 to $50 million

Blend Biosciences, Inc.: Raise no. 4, Jan 2017

Investors in this round

7 investors had bought by the notice of Feb 9, 2017: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew J. Fromkin · Executive Officer, Director
  • Leila J. Alland · Executive Officer
  • Richard J. Wooster · Executive Officer
  • Aymeric S. Sallin · Director
  • Dennis S. Ausiello · Director
  • Frank S. Torti · Director
  • Guido S. Magni · Director
  • James J. Barrett · Director
  • Nilesh J. Kumar · Director
  • Omid J. Farokhzad · Director
  • Robert S. Langer, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Fromkin, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 9, 2017. Read the notice at the SEC.

equitySEC
Jan 2016$38 MNo. 3$10 to $50 million

Blend Biosciences, Inc.: Raise no. 3, Jan 2016

Investors in this round

8 investors had bought by the notice of Feb 9, 2017: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$38 M of $38 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$720,000
Paid to its own people
$2,500,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Fromkin · Executive Officer, Director
  • Leila C. Alland · Executive Officer
  • Richard C. Wooster · Executive Officer
  • Aymeric S. Sallin · Director
  • Dennis C. Ausiello · Director
  • Edwin M. Kania · Director
  • Frank C. Torti · Director
  • James Barrett · Director
  • Nilesh C. Kumar · Director
  • Omid C. Farokhzad · Director, Promoter
  • Robert S. Langer · Director, Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MTS Securities, LLC (CRD 104059) · New York, New YorkSold in CA, CT, FL, IL, MA, NJ, NY, and outside the US

Signed by Andrew Fromkin, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 9, 2017. Read the notice at the SEC.

equity, optionsSEC
Dec 2012$21 MNo. 2$10 to $50 million

Blend Biosciences, Inc.: Raise no. 2, Dec 2012

Investors in this round

9 investors had bought by the notice of Dec 24, 2013: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$21 M of $21 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark S. Iwicki · Executive Officer, Director
  • Aymeric S. Sallin · Director
  • Edwin M. Kania · Director
  • James Barrett · Director
  • Omid C. Farokhzad · Director
  • Peter Barton Hutt · Director
  • Robert S. Langer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark Iwicki, President and CEO. Source: SEC Form D and 1 amendment, newest notice filed Dec 24, 2013. Read the notice at the SEC.

equitySEC
Aug 2011$3 MNo. 1$2 to $10 million

Blend Biosciences, Inc.: Raise no. 1, Aug 2011

Investors in this round

3 investors had bought by the notice of Sep 2, 2011: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Barton Quillen · Executive Officer
  • Shadi Barton Aryanpour · Executive Officer
  • Aymeric S. Sallin · Director
  • David S. Berry · Director
  • James S. Barrett · Director
  • Omid Farokhzad · Director
  • Peter Barton Hutt · Director
  • Robert S. Langer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey Quillen, Secretary. Source: SEC Form D, newest notice filed Sep 2, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Blend Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2021).

    SEC Form D · Sep 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2021

That is all the official record says: Blend Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Blend Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 13 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Blend Biosciences, Inc.
NameRoleNamed in
Brian RobertsExecutive officerSep 2021
Andrew J. FromkinExecutive officerDec 2019
Andrew FromkinExecutive officerFeb 2017
Leila C. AllandExecutive officerFeb 2017
Leila J. AllandExecutive officerFeb 2017
Richard C. WoosterExecutive officerFeb 2017
Richard J. WoosterExecutive officerFeb 2017
Mark S. IwickiExecutive officerDec 2013
Jeffrey Barton QuillenExecutive officerSep 2011
Shadi Barton AryanpourExecutive officerSep 2011
Aymeric SallinDirectorSep 2021
Brian RobertsDirectorSep 2021
Dennis AusielloDirectorSep 2021
Guido MagniDirectorSep 2021
Michael MetzgerDirectorSep 2021
Nilesh KumarDirectorSep 2021
Andrew J. FromkinDirectorDec 2019
Aymeric J. SallinDirectorDec 2019
Dennis J. AusielloDirectorDec 2019
Guido J. MagniDirectorDec 2019
Michael J. MetzgerDirectorDec 2019
Nilesh J. KumarDirectorDec 2019
Omid J. FarokhzadDirectorDec 2019
Robert J. LangerDirectorDec 2019
Andrew FromkinDirectorFeb 2017
Aymeric S. SallinDirectorFeb 2017
Dennis C. AusielloDirectorFeb 2017
Dennis S. AusielloDirectorFeb 2017
Edwin M. KaniaDirectorFeb 2017
Frank C. TortiDirectorFeb 2017
Frank S. TortiDirectorFeb 2017
Guido S. MagniDirectorFeb 2017
James BarrettDirectorFeb 2017
James J. BarrettDirectorFeb 2017
Nilesh C. KumarDirectorFeb 2017
Omid C. FarokhzadDirectorFeb 2017
Robert S. LangerDirectorFeb 2017
Robert S. Langer, Jr.DirectorFeb 2017
Mark S. IwickiDirectorDec 2013
Peter Barton HuttDirectorDec 2013